Search

Juan A. Torres

Examiner (ID: 18450, Phone: (571)272-3119 , Office: P/2634 )

Most Active Art Unit
2634
Art Unit(s)
2631, 2634, 2636, 2611
Total Applications
1774
Issued Applications
1502
Pending Applications
75
Abandoned Applications
208

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17096948 [patent_doc_number] => 20210284739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => ANTI-CD74 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODIES AND METHODS OF USING ANTI-CD74 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/196026 [patent_app_country] => US [patent_app_date] => 2021-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46179 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17196026 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/196026
ANTI-CD74 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODIES AND METHODS OF USING ANTI-CD74 ANTIBODIES Mar 8, 2021 Abandoned
Array ( [id] => 18283629 [patent_doc_number] => 20230099101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => SERINE PROTEASE INHIBITORS FOR SUPPRESSING OR PREVENTING ANAPHYLACTIC REACTION [patent_app_type] => utility [patent_app_number] => 17/908621 [patent_app_country] => US [patent_app_date] => 2021-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6963 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17908621 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/908621
SERINE PROTEASE INHIBITORS FOR SUPPRESSING OR PREVENTING ANAPHYLACTIC REACTION Mar 4, 2021 Pending
Array ( [id] => 17083403 [patent_doc_number] => 20210278409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => METHODS FOR DIAGNOSING HEMATOLOGICAL CANCERS [patent_app_type] => utility [patent_app_number] => 17/191974 [patent_app_country] => US [patent_app_date] => 2021-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15502 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17191974 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/191974
METHODS FOR DIAGNOSING HEMATOLOGICAL CANCERS Mar 3, 2021 Abandoned
Array ( [id] => 16899035 [patent_doc_number] => 20210177951 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => ENGINEERED CELLS & METHODS [patent_app_type] => utility [patent_app_number] => 17/179815 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42227 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17179815 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/179815
ENGINEERED CELLS & METHODS Feb 18, 2021 Abandoned
Array ( [id] => 16885465 [patent_doc_number] => 20210171660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => TARGETED DELIVERY METHODS AND COMPOSITIONS FOR ANTIHISTAMINES [patent_app_type] => utility [patent_app_number] => 17/175871 [patent_app_country] => US [patent_app_date] => 2021-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175871 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/175871
TARGETED DELIVERY METHODS AND COMPOSITIONS FOR ANTIHISTAMINES Feb 14, 2021 Abandoned
Array ( [id] => 18800077 [patent_doc_number] => 11833223 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-05 [patent_title] => Antibodies, pharmaceutical compositions and methods [patent_app_type] => utility [patent_app_number] => 17/160282 [patent_app_country] => US [patent_app_date] => 2021-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 49004 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17160282 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/160282
Antibodies, pharmaceutical compositions and methods Jan 26, 2021 Issued
Array ( [id] => 19794332 [patent_doc_number] => 12235272 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-25 [patent_title] => Screening and assessment of potentially malignant oral lesions [patent_app_type] => utility [patent_app_number] => 17/147681 [patent_app_country] => US [patent_app_date] => 2021-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 39 [patent_no_of_words] => 17092 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 162 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17147681 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/147681
Screening and assessment of potentially malignant oral lesions Jan 12, 2021 Issued
Array ( [id] => 16946774 [patent_doc_number] => 20210205465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY [patent_app_type] => utility [patent_app_number] => 17/146178 [patent_app_country] => US [patent_app_date] => 2021-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17146178 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/146178
ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY Jan 10, 2021 Abandoned
Array ( [id] => 18158742 [patent_doc_number] => 20230025334 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/788149 [patent_app_country] => US [patent_app_date] => 2020-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17788149 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/788149
COMPOSITIONS AND USES THEREOF Dec 23, 2020 Abandoned
Array ( [id] => 16932445 [patent_doc_number] => 20210198334 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => Anti-Tumour Response to Modified Self-Epitopes [patent_app_type] => utility [patent_app_number] => 17/131532 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25913 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17131532 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/131532
Anti-Tumour Response to Modified Self-Epitopes Dec 21, 2020 Abandoned
Array ( [id] => 16900779 [patent_doc_number] => 20210179695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => NOVEL FUNGAL TOXINS AND METHODS RELATED TO THE SAME [patent_app_type] => utility [patent_app_number] => 17/118594 [patent_app_country] => US [patent_app_date] => 2020-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17118594 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/118594
NOVEL FUNGAL TOXINS AND METHODS RELATED TO THE SAME Dec 9, 2020 Abandoned
Array ( [id] => 16873317 [patent_doc_number] => 20210166784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => NEOANTIGEN IDENTIFICATION, MANUFACTURE, AND USE [patent_app_type] => utility [patent_app_number] => 17/101522 [patent_app_country] => US [patent_app_date] => 2020-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 95432 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17101522 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/101522
NEOANTIGEN IDENTIFICATION, MANUFACTURE, AND USE Nov 22, 2020 Abandoned
Array ( [id] => 17156481 [patent_doc_number] => 20210317532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => GENETIC ALTERATIONS IN ISOCITRATE DEHYDROGENASE AND OTHER GENES IN MALIGNANT GLIOMA [patent_app_type] => utility [patent_app_number] => 17/091658 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20224 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17091658 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/091658
GENETIC ALTERATIONS IN ISOCITRATE DEHYDROGENASE AND OTHER GENES IN MALIGNANT GLIOMA Nov 5, 2020 Abandoned
Array ( [id] => 16976218 [patent_doc_number] => 20210220455 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => COMPOSITIONS AND METHODS FOR PERSONALIZED NEOPLASIA VACCINES [patent_app_type] => utility [patent_app_number] => 17/089408 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60516 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17089408 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/089408
COMPOSITIONS AND METHODS FOR PERSONALIZED NEOPLASIA VACCINES Nov 3, 2020 Pending
Array ( [id] => 17141750 [patent_doc_number] => 20210309762 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => Bispecific Antibodies That Bind to CD38 and CD3 [patent_app_type] => utility [patent_app_number] => 17/086213 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17086213 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/086213
Bispecific antibodies that bind to CD38 and CD3 Oct 29, 2020 Issued
Array ( [id] => 16854953 [patent_doc_number] => 20210155698 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => ANTIBODIES THAT BIND EGFR AND ERBB3 [patent_app_type] => utility [patent_app_number] => 17/076143 [patent_app_country] => US [patent_app_date] => 2020-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23797 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17076143 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/076143
Methods of treating a subject having an EGFR-positive and/or ErbB-3-positive tumor Oct 20, 2020 Issued
Array ( [id] => 16674640 [patent_doc_number] => 20210063403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => MATERIALS AND METHODS FOR PERFORMING HISTOCHEMICAL ASSAYS FOR HUMAN PRO-EPIREGULIN AND AMPHIREGULIN [patent_app_type] => utility [patent_app_number] => 16/949252 [patent_app_country] => US [patent_app_date] => 2020-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27402 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16949252 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/949252
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin Oct 20, 2020 Issued
Array ( [id] => 16613667 [patent_doc_number] => 20210032320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => ANTI-PCNA MONOCLONAL ANTIBODIES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/074919 [patent_app_country] => US [patent_app_date] => 2020-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16438 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17074919 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/074919
Anti-PCNA monoclonal antibodies and use thereof Oct 19, 2020 Issued
Array ( [id] => 19150080 [patent_doc_number] => 11974970 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-07 [patent_title] => Muscular atrophy-inducing agent using hypometabolism-inducing substance T1AM, and use thereof in treating muscular hypertrophy [patent_app_type] => utility [patent_app_number] => 17/029791 [patent_app_country] => US [patent_app_date] => 2020-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 34 [patent_no_of_words] => 7063 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17029791 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/029791
Muscular atrophy-inducing agent using hypometabolism-inducing substance T1AM, and use thereof in treating muscular hypertrophy Sep 22, 2020 Issued
Array ( [id] => 16750224 [patent_doc_number] => 20210102233 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => METHODS AND SYSTEMS FOR PREDICTING DRUG-RESPONSE [patent_app_type] => utility [patent_app_number] => 17/019971 [patent_app_country] => US [patent_app_date] => 2020-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17019971 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/019971
METHODS AND SYSTEMS FOR PREDICTING DRUG-RESPONSE Sep 13, 2020 Abandoned
Menu